Purchase this article with an account.
G. Zinzanella, A. M. Minnella, A. Scupola, M. C. Savastano, L. Ziccardi, S. Petroni, L. Montrone, D. Marangoni, B. Falsini, E. Balestrazzi; Intravitreal Bevacizumab in Proliferative Diabetic Retinopathy. Invest. Ophthalmol. Vis. Sci. 2007;48(13):1416.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the efficacy and safety of intravitreal bevacizumab in proliferative diabetic retinopathy (PDR) patients.
This interventional case series study included seven eyes of 7 patients with bilateral PDR: 6 eyes with PDR already treated with panretinal laser photocoagulation (PRP) and active new vessels (NV) and 1 eye with recurrent vitreous hemorrhages. All eyes were treated with a single intravitreal of 1.25 mg (0,05 ml) of bevacizumab and evaluated by optical coherence tomography (OCT) and fluorescein angiography (at baseline, one month and three months). All patients received or completed PRP after the injection.
All eyes (n=7) had a regression of all types of NV with an average improvement of visual acuity of 0.10 mean LogMAR units (±0.03, SE); the eye with recurrent vitreous hemorrhages had clearing of bleeding and improvement of 0.96 mean LogMAR units. The eyes with associated macular edema (n=4) had a mean reduction of macular thickness of 117 microns (±39.48, SE). These early effects allowed us to perform or complete safely PRP.
Intravitreal bevacizumab did not reveal any side effects and resulted in regression of neovascularizations and resolution of vitreous hemorrhages. Association of intravitreal bevacizumab with PRP could be more effective than PRP alone avoiding laser-related complications and vitreo-retinal surgical procedures.
This PDF is available to Subscribers Only